الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
Hepatocellular carcinoma (HCC) is the fifth world malignant tumour
and the most prevalent type of liver cancer, with a high incidence and
morbidity. chronic hepatitis B (HBV) and C (HCV), hepatic cirrhosis,
diabetes, nonalcoholic steatohepatitis (NASH), aflatoxin exposure,
obesity, and nonalcoholic fatty liver disease (NAFLD) are all variables
that influence the incidence of HCC.
In Egypt, hepatocellular carcinoma is a major health issue. HCV
infection plays a significant influence in the development of liver cancer.
MicroRNAs are small, non-coding RNA molecules with 21–30
nucleotides in length that attach to the 3 untranslated region (UTR) of
mRNAs to negatively regulate target genes. These complexes are posttranscriptional
effectors that are involved in RNA-mediated interference
and pathological conditions including tumor by affecting the expression
of genes in numerous biological processes which may have a role in the
Pathogenesis of Hepatocellular Carcinoma.
MiRNAs are tissue-specific and remain stable in plasma or serum in
a form that is protected from endogenous RNase activity even when
exposed to unstable environments such as high temperatures or low pH, so
increase their potential use as noninvasive biomarkers in disease detection.
There are various studies investigating the function of miRNAs as
diagnostic or prognostic biomarkers in human cancers, including HCC.
miRNAs can serve as oncogenes or tumor suppressor genes depend on
the cellular affection of their target’s conditions.
Summary
65
The aim of the present study was to detect the role of circulating
miR-130b and miR-125b expression in development and pathogenesis of
HCC.
It was a prospective case-control study that was conducted on 80 patients
and 40 healthy individuals ; Groups were divided as following.
group I (control group): included 40 healthy individuals.
group II: included 40 patients with chronic cirrhosis.
group III: included 40 patients with Hepatocellular carcinoma.
All patients were assessed in terms of clinical and laboratory data, as
well as the Child–Pugh score, and BCLC stage. The time between
enrollment in our study (blood withdrawal) and death or the last
documented contact with the patient was used to calculate the overall
survival time.
Patients more than 18 years of age who had liver cirrhosis and/or a
primary HCC diagnosis determined by either histology examination, or
two dynamic imaging studies were eligible for inclusion.
Summary of our results:
Sex and age were insignificantly different among the three groups.
ALT, AST, and total bilirubin were significantly higher in group III
than group I and group II and were significantly higher in group II
than group I (P value <0.001).
Serum albumin and platelet count were significantly lower in group
III than group I and II and were significantly lower in group II than
group I (P value <0.001). AFP and GGT were significantly higher in
Summary
66
group III than group I and II (P value <0.001) and were
insignificantly different between group I and group II.
RQ miR-130 was significantly higher in group III than group I and
II and was significantly higher in group II than group I
(P value <0.001). RQ miR-125 was significantly lower in group III
than group I and II and was significantly lower in group II than
group I (P value <0.001).
TP was significantly higher in group II than group III (P value
<0.001). WBCs and ALP were significantly lower in group II than
group III (P value <0.001). HB was insignificantly different between
the two groups.
In group III, 22 (55%) patients had ascites, 37(92.5%) patients had
metastasis and 20(50%) patients had spleenic affection. Regarding
tumor size, it ranged from 1.5 to 5 cm with a mean ± SD of 2.9 ±
0.5 cm as 25(62.5%) patients had tumor size ≤3 cm and 15(37.5%)
patients had tumor size >3 cm.
In group III, RQ miR-130 had a significant positive correlation
with AFP (r= 0.441, P= 0.004) and tumor size (r= 0.541,
P<0.001). RQ miR-130 had an insignificant correlation with age,
ALT, AST, serum albumin, total bilirubin, GGT, TP, HB and
WBCs.
RQ miR-125 had a significant positive correlation with platelet (r=
0.319, P= 0.045). RQ miR-125 had an insignificant correlation with
age, ALT, AST, serum albumin, total bilirubin, AFP, GGT, TP, HB,
WBCs and tumor size.